Clinical Trial Update: Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating the combination of dacomitinib and osimertinib for patients with advanced EGFR-mutant non-small cell lung cancer has complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Dacomitinib (dacomitinib)
• Osimertinib (osimertinib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Metastatic Non-small Cell Lung Cancer | Phase 1 | Status: COMPLETED